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Shiga toxin 1 (Stx1) transiently increases the expression of proinflammatory cytokines by macrophage-like
THP-1 cells in vitro. Increased cytokine production is partly due to activation of the translation initiation
factor eIF4E through a mitogen-activated protein kinase (MAPK)- and Mnk1-dependent pathway. eIF4E
availability for translation initiation is regulated by association with eIF4E binding proteins (4E-BP). In this
study, we showed that Stx1 transiently induced 4E-BP hyperphosphorylation, which may release eIF4E for
translation initiation. Phosphorylation of 4E-BP at priming sites T37 and T46 was not altered by Stx1 but was
transiently increased at S65, concomitant with increased cytokine expression. Using kinase inhibitors, we
showed that 4E-BP phosphorylation was dependent on phosphatidylinositol 3-kinase (PI3K), Akt, and mam-
malian target of rapamycin (mTOR) activation but did not require MAPKs. Stx1 treatment resulted in
increased levels of cytosolic Ca2. PI3K and Akt activation led to the phosphorylation and inactivation of the
positive cytokine regulator glycogen synthase kinase 3/ (GSK-3/). PI3K, Akt, and mTOR inhibitors and
small interfering RNA knockdown of Akt expression all increased, whereas a GSK-3/ inhibitor decreased,
Stx1-induced soluble tumor necrosis factor alpha and interleukin-1 production. Overall, these findings
suggest that despite transient activation of 4E-BP, the PI3K/Akt/mTOR pathway negatively influences cytokine
induction by inactivating the positive regulator GSK-3/.
Bacteria producing Shiga toxins (Stxs), a family of function-
ally related AB5 toxins, continue to be a significant public
health concern. After ingestion of contaminated foods or wa-
ter, the bacteria colonize the large intestine and cause bloody
diarrhea with the potential to progress to life-threatening sys-
temic complications including acute renal failure and central
nervous system complications (45). The toxins are internalized
and transported via the trans-Golgi network and Golgi appa-
ratus to the endoplasmic reticulum (ER) and finally into the
cytoplasm (39). It is well established that Stxs are protein
synthesis inhibitors. Toxin A subunits mediate protein synthe-
sis inhibition by depurination of a single adenine residue lo-
cated on a stem-loop structure near the 3 end of 28S rRNA of
the 60S ribosomal subunit (11, 41). The toxins bind cells
through interaction of pentameric B subunits with the neutral
membrane glycolipid globotriaosylceramide (Gb3) (28).
In addition to protein synthesis inhibition, it has become
clear that Stxs also activate host cell signaling pathways in-
volved in the induction of cytokine and chemokine expression
(3, 5, 20, 34, 51). Among the cytokines induced by Stxs, tumor
necrosis factor alpha (TNF-) and interleukin-1 (IL-1) in-
crease Gb3 expression on human vascular endothelial cells in
vitro (35, 50). Thus, the host innate immune response to the
toxins may participate in the development of intestinal, renal,
and central nervous system vascular lesions characteristic of
bloody diarrhea and postdiarrheal sequelae. A more complete
understanding of the signaling mechanisms activated by Stxs
will be important for the development of therapeutic ap-
proaches for treating this emerging infectious disease. The
precise cellular sources of cytokines in patients with bloody
diarrhea or systemic complications are unknown. However,
macrophages produce soluble cytokines and chemokines in
response to microbes and microbial products. Furthermore,
monocytic infiltration of the lamina propria and renal intersti-
tial spaces was observed in animals administered Stxs (23, 46).
Stxs regulate cytokine expression by human macrophage-like
THP-1 cells through transcriptional and translational mecha-
nisms. Transcriptional regulation involves prolonged activation
of the stress-associated protein kinases p38 and Jun N-terminal
protein kinase (JNK), transient activation of extracellular sig-
nal-regulated kinases 1 and 2 (ERK1/2), and activation of the
transcription factors NF-B and AP-1 (5, 38). Toxin-mediated
translational control of cytokine expression involves, in part,
stabilization of cytokine and chemokine mRNA transcripts
(19, 20, 49).
In eukaryotic cells, initiation is the rate-limiting step con-
trolling translation (37). Initiation involves modulation of pro-
tein-protein and protein-RNA interactions and is under the
control of diverse signal transduction pathways, including mi-
togen-activated protein kinases (MAPKs) (25, 42). Translation
initiation begins with the formation of eIF4F, a 43S preinitia-
tion complex containing the 40S rRNA subunit, eukaryotic
initiation factors (eIFs), and Met-tRNA (17). Formation of
this complex depends on activation (phosphorylation) and
availability of initiation factor 4E (eIF4E) following release
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from cytosolic sequestering proteins called 4E-binding proteins
(4E-BPs). Treatment of macrophage-like THP-1 cells with
Shiga toxin 1 (Stx1) resulted in increased eIF4E activation, and
inhibitors that blocked toxin-induced eIF4E activation dimin-
ished cytokine production (5). The affinity of 4E-BPs for eIF4E
is regulated by the phosphorylation status of at least six 4E-BP
serine/threonine residues (T37, T46, S65, T70, S83, and S112),
with 4E-BP hyperphosphorylation associated with eIF4E re-
lease. In response to signals such as growth factors, 4E-BPs
appear to be phosphorylated in a stepwise manner, with phos-
phorylation of the amino-terminal T37 and T46 residues func-
tioning as a priming step for subsequent phosphorylation
events (16). Following 4E-BP hyperphosphorylation at S65 and
T70, released eIF4E may be phosphorylated and bind to the
5-methylguanosine (m7GpppN, where N is any nucleotide)
cap of mRNA transcripts to initiate translation. In mammalian
cells, 4E-BP hyperphosphorylation is regulated in part by sig-
naling through phosphatidylinositol 3-kinase (PI3K), Akt (or
protein kinase B), and mammalian target of rapamycin
(mTOR) (15, 30). The influence of the PI3K/Akt/mTOR path-
way on cytokine expression has been reported to be positive or
negative depending on the cytokine and cell type studied (18,
31). Pathways regulating Stx-induced 4E-BP activation and
eIF4E release are not well understood. In this study, we have
shown that Stx1 treatment of THP-1 cells results in transient
4E-BP hyperphosphorylation. Stx1 signals 4E-BP activation
through the PI3K/Akt/mTOR pathway, and a toxin enzymatic
mutant appears to partially activate this pathway. Stx1 treat-
ment triggered increased cytosolic Ca2 levels and phosphor-
ylation (inactivation) of the positive cytokine regulator glyco-
gen synthase kinase 3/ (GSK-3/). We examined the role
of Stx1-induced PI3K/Akt/mTOR signaling in cytokine pro-
duction. Inhibitors of the PI3K/Akt/mTOR pathway and small
interfering RNA (siRNA) knockdown of Akt expression in-
creased, while a GSK-3/ inhibitor decreased, production of
TNF- and IL-1 24 h after Stx1 treatment, suggesting that
despite triggering the transient activation of 4E-BPs, the PI3K/
Akt/mTOR pathway primarily plays a negative role in regulat-
ing cytokine production.
MATERIALS AND METHODS
Antibodies and reagents. Rabbit anti-human PI3K phospho-p85 antibody was
from Santa Cruz Biotechnology Inc. (Santa Cruz, CA). Anti-human phospho-
4E-BP, anti-phospho-Akt, anti-phospho-GSK-3/ antibodies, Akt kinase assay
kits, and Akt siRNA were from Cell Signaling Technology (Beverly, MA). The
fluorescent calcium indicator Fluo-5F acetoxymethyl ester (AM) was obtained
from Molecular Probes, Inc. (Eugene, OR). The PI3K inhibitors wortmannin
and LY294002, Akt kinase inhibitor VIII, mTOR inhibitor rapamycin, JNK
inhibitor SP600125, p38 MAPK inhibitor SB203580, ERK1/2 inhibitor PD98059,
and GSK-3/ inhibitor IX were purchased from Calbiochem (San Diego, CA).
TNF- and IL-1 enzyme-linked immunosorbent assay (ELISA) kits were from
R&D Systems Inc., Minneapolis, MN. Immunoprecipitation kits were purchased
from Amersham Pharmacia Biotech (Piscataway, NJ). All other reagents were
obtained from Sigma Chemical Co. (St. Louis, MO).
Toxins. Stx1 was purified as described previously (47). Briefly, Escherichia coli
DH5(pCKS112) expressing the stx1 operon was grown in Luria-Bertani broth
with ampicillin. Stx1 was purified from cell lysates by sequential ion exchange,
chromatofocusing, and immunoaffinity chromatography. The purity of toxins was
tested by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) with silver staining and Western blot analysis with anti-Stx1 monoclonal
antibody. Endotoxin levels in toxin preparations contained 0.1 ng of endotoxin
per ml as determined by the Limulus amoebocyte lysate assay (Associates of
Cape Cod, East Falmouth, MA). Purified Stx1 holotoxin containing a double
mutation (E167Q and R170L) in the A subunit which dramatically reduces
enzymatic activity (32) was the kind gift of Shinji Yamasaki, Osaka Prefecture
University (Osaka, Japan). Purified Stx1 B subunit was the kind gift of Cheleste
Thorpe, Tufts University New England Medical Center (Boston, MA). Purified
lipopolysaccharides (LPS) derived from E. coli O111:B4 were purchased from
Sigma.
Cell culture and differentiation. The human myelogenous leukemia cell line
THP-1 was purchased from American Type Culture Collection (Rockville, MD)
and cultured in RPMI-1640 medium (Gibco-BRL, Grand Island, NY) supple-
mented with penicillin (100 U/ml), streptomycin (100 g/ml), and 10% fetal
bovine serum (HyClone Laboratories, Logan, UT; or Gemini Bioproducts, West
Sacramento, CA). Cells were grown and maintained at 37°C in 5% CO2 in a
humidified incubator. To differentiate THP-1 cells to the adherent, macrophage-
like state, cells were incubated with phorbol 12-myristate 13-acetate (50 ng/ml)
for 48 h. The medium was then replaced with medium lacking phorbol 12-
myristate 13-acetate, with daily medium changes, for 3 days prior to use of the
cells in experiments.
Preparation of cell lysates, immunoprecipitation, and Western blot analysis.
THP-1 cells (5  106 cells/ml) were washed in cold Dulbecco’s phosphate-
buffered saline (PBS) and cultured in RPMI-1640 with 0.5% fetal bovine serum
(FBS) for 18 h to reduce endogenous kinase activity. Cells were stimulated with
Stx1, an Stx1 enzymatic mutant (Stx1A	; 400 ng/ml), or purified Stx1 B subunits
(800 ng/ml). We previously reported that this Stx1 concentration resulted in a
transient increase in total protein synthesis by THP-1 cells lasting 2 h, after which
protein synthesis decreased (12). Cells were harvested and lysed at 4°C in mod-
ified radioimmunoprecipitation assay buffer (1.0% Nonidet P-40, 1.0% Na de-
oxycholate, 150 mM NaCl, 1 mM Na2EDTA, 50 mM Tris-HCl [pH 7.5], 0.25 mM
Na pyrophosphate, 2.0 mM [each] sodium vanadate [NaVO4] and sodium fluo-
ride [NaF], 10 g/ml aprotinin, 1.0 g/ml leupeptin and pepstatin, and 200 mM
phenylmethylsulfonyl fluoride). Extracts were collected and cleared by centrifu-
gation at 15,000 g for 10 min. Cleared extracts were stored at	80°C until used.
The protein content in cell extracts and cytosolic fractions prepared from stim-
ulated THP-1 cells was determined using the DC protein assay kit (Bio-Rad,
Hercules, CA). For immunoprecipitation reactions, extracts containing 300 g
protein were precleared with 20 l protein A:G (equal ratio) for 1 h. Anti-p85
antibody was added, with incubation overnight. Then, 20 l of protein A:G was
added for 2 h. Beads were pelleted by centrifugation, washed three times, and
boiled with 2 sample buffer. Proteins were separated by 8% SDS-PAGE. For
Western blotting, equal amounts of proteins (60 to 80 g protein per gel lane)
were separated by 8% or 12% Tris-glycine SDS-PAGE and transferred to nitro-
cellulose membranes. Membranes were blocked with 5% milk prepared in TBST
(20 mM Tris [pH 7.6], 137 mM NaCl, containing 0.1% Tween 20) and incubated
with primary antibodies specific for 4E-BP, PI3K phospho-p85, or Akt in 5%
bovine serum albumin in Tris-buffered saline and 0.1% Tween 20 overnight at
4°C and then with corresponding secondary antibodies (anti-rabbit/mouse im-
munoglobulin G [IgG] coupled to horseradish peroxidase [HRP]) for 2 h at room
temperature. Bands were visualized using the Western Lightning chemilumines-
cence system (NEN-Perkin Elmer, Boston, MA).
Analysis of eIF4E and 4E-BP dissociation. m7GTP-Sepharose 4B was ob-
tained from Amersham Pharmacia Biotech (Piscataway, NJ). THP-1 cells (1.0 
107 cells/ml) were washed and stimulated as described above. Cells were lysed at
4°C in lysis buffer (1% Nonidet P-40, 0.25% Na deoxycholate, 150 mM NaCl, 50
mM HEPES [pH 7.5], 25 mM glycerol phosphate, 2.0 mM [each] NaVO4, NaF,
and EDTA, 10 g/ml aprotinin, 1.0 g/ml leupeptin and pepstatin, and 200 mM
phenylmethylsulfonyl fluoride). Extracts were collected and cleared by centrifu-
gation at 15,000  g for 10 min. The protein content in cell extracts was deter-
mined using the DC protein assay kit (Bio-Rad, Hercules, CA). Equal amounts
of protein (300 g) were precleared with Sepharose 4B (30 l of settled bed
volume) for 1 h, and then an equal volume of m7GTP-Sepharose 4B was added
with incubation at 4°C overnight with gentle shaking. Precipitates and superna-
tants were collected. Precipitates were washed three times with lysis buffer, and
proteins from precipitates or supernatants were separated by 15% SDS-PAGE.
Western blotting was performed with anti-phospho-eIF4E and anti-rabbit IgG-
HRP antibodies. For loading controls, the same blots were stripped and re-
probed with antibodies against total eIF4E. The same samples were run in
parallel for blotting with various anti-phospho-4E-BP antibodies.
Akt kinase activity assay. Akt kinase activity was determined using kits pur-
chased from Cell Signaling Technology according to the manufacturer’s instruc-
tions. Briefly, THP-1 cells (5  106 cells/ml) were untreated or treated with Stx1
(400 ng/ml), washed with ice-cold PBS, and lysed with ice-cold lysis buffer
provided with the kit. Samples were incubated for 20 min on ice. Cell lysates were
centrifuged, and supernatants were obtained. Protein concentrations were mea-
sured using Bio-Rad DC protein assay kits. Equal amounts of protein (300 g)
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were precleared with protein A-protein G (1:1) Sepharose. Immobilized anti-Akt
monoclonal antibody agarose was added and incubated at 4°C overnight with
gentle shaking. Immunoprecipitates were washed three times with lysis buffer
and twice with Akt kinase buffer containing 200 M ATP and 1.0 g GSK-3
fusion protein. The sample proteins were separated by 12% SDS-PAGE, and
Western blotting was performed with anti-phospho-GSK-3/ and anti-rabbit
IgG-HRP antibodies. Band intensities were quantified and induction calculated
as the stimulated protein band intensity values divided by unstimulated control
protein band intensity values after normalizing for loading controls.
Calcium (Ca2) measurement. Fluo-5F AM, a cell-permeable fluorescent
indicator of intracellular Ca2 with an excitation wavelength of 488 nm and
emission at 530 nm, was used. Fluo-5F AM has a relatively low Ca2-binding
affinity, making it suitable for detecting intracellular Ca2 levels in the range of
1.0 M to 1.0 mM. Low Ca2-binding affinities are ideal for detecting high
concentrations of Ca2 released from ER stores (22, 33). Differences in fluo-
rescence, with or without toxin treatment, were measured using the Zeiss Stallion
live cell imaging system (Carl Zeiss Microscopy, Gottingen, Germany) equipped
with an argon laser. The cells were incubated with Fluo-5F AM (3.0 M) for 45
min at 37°C and 5% CO2. Basal fluorescence was measured for 10 min. Cells
were then stimulated with Stx1 (400 ng/ml) and fluorescence measurements
continued for 1 h. Finally, fluorescence was measured after adding the ER-
localized Ca2-dependent ATPase inhibitor thapsigargin (10 M) for 10 min.
Fluorescence intensity was measured in the presence of Ca2-containing me-
dium and Ca2-free medium (made by adding 2.0 mM EGTA) to identify
intracellular and extracellular sources of Ca2. Normalized fluorescence inten-
sity (from unstimulated cells) was plotted against time from three independent
experiments.
ELISA for soluble TNF- and IL-1 production. Cell supernatants were
collected from adherent THP-1 cells (2  106 cells/ml) stimulated with Stx1 (400
ng/ml) for 24 h with or without pretreatment for 1 h with wortmannin, Akt
inhibitor VIII, rapamycin, or GSK-3/ inhibitor IX. Supernatants for TNF-
and IL-1 detection were added in duplicate wells to ELISA plates (R&D
Systems) and the assay performed according to the manufacturer’s protocol.
Absorbance was measured at 450 nm and 570 nm using a microtiter plate reader
(Dynatech MR5000; Dynatech Laboratories, Chantilly, VA). Mean cytokine
values (pg/ml) from three independent experiments were calculated and ex-
pressed as means 
 standard errors of the means (SEM).
siRNA transfection. THP-1 cells (2  106 cells/well) were differentiated in
12-well plates as described above. Two hours before transfection, medium was
replaced with Dulbecco’s modified Eagle medium plus 10% FBS. Complexes of
transfection reagent and Akt-specific and nonspecific siRNAs were prepared
according to the manufacturer’s instructions (TransIT-TKO transfection reagent;
Mirus Bio Corporation, Madison, WI). After addition of the siRNA complexes,
cells were incubated for 48 h at 37°C in 5% CO2. Two hours before Stx1
stimulation, viable cells were washed with 1 PBS, and RPMI plus 10% FBS was
added to the cells. Cells were treated with Stx1 for 24 h. Supernatants were
collected for measurement of soluble cytokines by ELISA. Data are expressed as
mean cytokine values (pg/ml) 
 SEM from at least three independent experi-
ments. To assess transfection efficiency, cell lysates were prepared and Western
blotting performed using antibodies directed against total Akt and actin.
Statistical analyses. For statistical analysis of kinetic data for 4E-BP, PI3K,
and phospho-p85 activation, Akt kinase assays, and cytokine expression, signif-
icance was calculated using Student’s t test (Excel, Microsoft Corp., Redmond,
WA). For Ca2 measurements, a one-tailed simple t test with Welch’s correction
was used for calculation of significance. For Ca2 measurements in the presence
of EGTA, analysis of variance followed by Tukey’s multiple comparison test was
used for calculating significance. Significance was defined as a P value of 0.05.
RESULTS
Stx1 induces transient phosphorylation of 4E-BP at serine
65. Sequential phosphorylation of 4E-BP at multiple threonine
and serine residues is necessary for the release eIF4E, which
may lead to increased formation of translation initiation com-
plexes and translation of mRNA transcripts. To examine
whether Stxs induce sequential phosphorylation of 4E-BP,
macrophage-like THP-1 cells were stimulated with purified
FIG. 1. Stx1 induces transient 4E-BP phosphorylation at serine 65 in THP-1 cells. Adherent macrophage-like THP-1 cells were stimulated with
Stx1 (A) or Stx1A	 (C) (400 ng/ml) for 1 to 16 h (Stim. time). Cell lysates were prepared and Western blotting performed using site-specific
antibodies for 4E-BP phosphothreonine or phosphoserine residues. Blots were stripped and reprobed with antibodies against total 4E-BP to
control for equal protein loading (bottom panels). C, lysates prepared from control cells maintained for 16 h without toxin. Band intensities from
at least four independent experiments using Stx1 (B) or Stx1A	 (D) were measured by densitometry, and the data are expressed as mean n-fold
changes 
 SEM relative to results for untreated control cells. Asterisks (*) denote significant differences (P 0.05) versus results for control cells.
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Stx1, mutated Stx1 holotoxin molecules with dramatically re-
duced enzymatic activity (Stx1A	), or purified Stx1 B subunits.
At various time points after treatment, cells were lysed and
Western blotting performed using site-specific antiphospho-
threonine or antiphosphoserine antibodies. Representative West-
ern blots are shown in Fig. 1A and C, and mean band intensi-
ties derived from at least four independent experiments are
shown in Fig. 1B and D. 4E-BP appeared to be constitutively
phosphorylated at positions T37, T46, and T70 in control (un-
stimulated) cells. Treatment with Stx1 failed to induce in-
creased phosphorylation at T37 and T46 and caused only mod-
est increases in T70 phosphorylation. In contrast, S65 was
minimally phosphorylated in control cells, and in response to
treatment with Stx1, 4E-BP was transiently phosphorylated at
S65, peaking at a 3.4-fold increase 1 h after toxin treatment and
declining over a 4-h time period (Fig. 1B). Blots were stripped
and reprobed with anti-4E-BP antibody to ensure equal pro-
tein loading at each time point. Given the transient nature of
4E-BP activation by Stx1, we examined S65 phosphorylation 30
min after toxin treatment and failed to detect 4E-BP activation
(data not shown). Mutant Stx1A	 holotoxin failed to alter
basal phosphorylation of 4E-BP at T37/46 but modestly in-
creased T70 and significantly increased S65 phosphorylation,
although peak activation levels were slightly less than that
induced by Stx1 (Fig. 1D). Purified Stx1 B subunits also trig-
gered 4E-BP phosphorylation at S65 (data not shown). These
data suggest that toxin enzymatic activity may not be necessary
for 4E-BP hyperphosphorylation.
Stx1 induces the dissociation of phospho-eIF4E and hyper-
phosphorylated 4E-BP. To show that Stx1-mediated 4E-BP
hyperphosphorylation leads to eIF4E dissociation, we per-
formed an affinity precipitation assay using m7GTP-Sepharose
4B beads. At various time points after toxin stimulation, cell
lysates were incubated with the beads and precipitates were
collected and analyzed by SDS-PAGE and Western blotting
with phospho-specific antibodies against eIF4E and 4E-BP. As
shown in Fig. 2A, upper panel, there was an increased associ-
ation of phospho-eIF4E with m7GTP-coated beads after 1 h
of toxin treatment, suggesting a transient dissociation from
4E-BP and increased binding to the 5-cap structure of
FIG. 2. Stx1 induces the dissociation of eIF4E from 4E-BP. Cell lysates from Stx1-treated THP-1 cells were incubated with m7GTP-Sepharose
4B beads. Beads were washed and Western blotting (WB) performed using antibodies specific for phosphorylated and total eIF4E (A) or
phosphorylated 4E-BP and total 4E-BP (B) in immunoprecipitates. (C) Western blotting of phosphorylated 4E-BP (S65) and total 4E-BP in
supernatants versus bead-containing immunoprecipitates. BC, bead control without cell lysates; C, control (unstimulated) cells; TCL, total cell
lysates; Sup, supernatants; Ppt, immunoprecipitates. Band intensities were measured by densitometry, and n-fold changes are expressed beneath
each lane. The data shown are representative of at least three independent experiments.
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mRNAs. Nonphosphorylated forms of eIF4E also bound the
beads, but differences in binding were not manifest over pro-
longed exposure of the cells to toxin (Fig. 2A, lower panel).
The data also showed that 4E-BP phosphorylated at the prim-
ing residues was associated with the m7GTP beads and eIF4E
(Fig. 2B, upper panel). However, 4E-BP phosphorylated at
T70 was only faintly detected, and S65 was not detected, in the
precipitates. Western blots of cell lysate supernatants showed
that hyperphosphorylated 4E-BP remained in the supernatant
and was not associated with the precipitates pulled down by
m7GTP beads (Fig. 2C). These data suggest that Stx1-induced
phosphorylation of 4E-BP at positions T70 and S65 is neces-
sary for eIF4E dissociation and m7GTP binding.
Stx1 activates PI3K. We have shown that eIF4E phosphor-
ylation requires the internalization and transport of enzymat-
ically active Stx1 and activation of the ribotoxic stress response
(5). Many growth factors and hormones regulate translation by
altering 4E-BP phosphorylation in a wortmannin- and rapam-
ycin-sensitive manner, indicating that PI3K, Akt, and mTOR
are involved in signaling pathways leading to 4E-BP activation
(30). To test the hypothesis that in addition to initiating the
ribotoxic stress response, Stx1 also initiates signaling through
the PI3K/Akt/mTOR pathway, we examined PI3K activation in
THP-1 cells treated with Stx1, an Stx1A	 mutant, or Stx1 B
subunits. Cell lysates were analyzed for PI3K activation using
an antibody directed against the phosphorylated p85 subunit
by Western blotting and immunoprecipitation. Immunoblots
were stripped and reprobed with total p85 antibody to ensure
equal protein loading at each time point. Stx1 rapidly induced
PI3K activation, with a 3.5-fold increase in activation at 1 h,
which peaked after 4 h, followed by a decline to basal (un-
stimulated) levels over 16 h (Fig. 3A). The A-subunit mutant
induced a 3.3-fold increase at 4 h posttreatment. Purified Stx1
B subunits stimulated a 3.5-fold increase in PI3K activation
with similar kinetics (data not shown). To verify the capacity of
Stx1 to functionally activate PI3K, we performed immunopre-
cipitation-Western analyses of lysates prepared from Stx1- or
Stx1A	 mutant-treated cells. In this assay, the p85 subunit of
PI3K is immunoprecipitated using anti-p85 antibodies, and the
immunoprecipitates are transferred to nitrocellulose mem-
branes and probed with anti-phospho-p85-specific antibodies.
Immunoprecipitates prepared from Stx1- and Stx1A	-treated
cells showed increased levels of activated PI3K, peaking 4 to
6 h after toxin treatment (Fig. 3B). These data suggest that
while enzymatically active Stx1 may mediate optimal PI3K
activation, the binding or internalization of Stx1A	 or Stx1 B
subunits may be sufficient to partially activate PI3K.
Stx1 induces increased cytosolic Ca2 levels. PI3K activa-
tion leads to the production of phospholipid second messenger
phosphatidylinositol-3,4,5-triphosphate, which may lead to
Ca2 release from ER stores after binding to ER membrane
phosphatidylinositol-3,4,5-triphosphate receptors (2). We rea-
soned that Stx1-induced PI3K activation would result in in-
creased cytosolic Ca2 levels. We investigated Stx1-induced
release of Ca2 using the fluorescent calcium indicator
Fluo-5F AM, which is a cell-permeable, relatively low-Ca2-
binding affinity marker suitable for measuring higher concen-
trations of Ca2 released from ER stores. After 10 min of
fluorescence measurements to establish basal intensity, the
addition of Stx1 or Stx1A	 is shown in Fig. 4A or C, respec-
tively. A slow but statistically significant (Fig. 4B and D) in-
crease in fluorescence intensity up to 1 h after toxin treatment
was detected. This slow increase in cytosolic Ca2 levels was
not detected in control (unstimulated) cells (data not shown).
Addition of the positive control thapsigargin, a compound that
prevents the uptake of cytosolic Ca2 into the ER, is also
shown in the figure. Increased fluorescence intensity was noted
after thapsigargin treatment, implicating the ER as the source
of intracellular Ca2. To examine the influx of extracellular
Ca2, we measured fluorescence in cells treated with Stx1 (Fig.
4E) or Stx1A	 (Fig. 4G) maintained in Ca2-chelated
(EGTA) medium. In the presence of EGTA, there was a sharp
increase in fluorescence intensity when Stx1 was added, and
cytosolic Ca2 levels increased with thapsigargin treatment.
However, significant continual increases in cytosolic Ca2 were
not detected after 1 h of toxin treatment when cells were
maintained in chelated medium (Fig. 4F and H). These data
indicate that Stx1 stimulation activates PI3K and Ca2 release
FIG. 3. Stx1 activates PI3K. (A) Adherent macrophage-like THP-1 cells were stimulated with Stx1 or inactive Stx1 holotoxin (Stx1A	) for 1
to 16 h. Cell lysates were prepared and Western blotting (WB) performed using antibodies specific for the phospho-p85 subunit of PI3K. Blots
were stripped and reprobed with antibodies against p85 PI3K for equal protein loading (bottom panels). C, lysates prepared from control cells
maintained for 16 h without toxin. Band intensities were measured by densitometry, and n-fold changes are expressed beneath each lane. Asterisks
(*) denote significant differences (P  0.05) for results with toxin treatment versus results for control cells. (B) Immunoprecipitation reactions
using anti-p85 PI3K antibodies were carried out with lysates prepared from Stx1- or Stx1A	 mutant-treated cells. Immunoprecipitates were
separated by SDS-PAGE, transferred to nitrocellulose, and probed using anti-phospho-p85 PI3K antibodies. C, control (unstimulated) cells; IgG,
antibody-only control; TCL, total cell lysates. Results shown are representative of at least three independent experiments.
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in THP-1 cells. Sources of increased cytosolic Ca2 may in-
clude the ER, but we cannot rule out additional influx from the
extracellular environment.
Stx1 activates Akt. Following phosphorylation of mem-
brane-associated phosphatidylinositol second messengers by
PI3K, a number of signaling pathways are activated, including
the serine/threonine kinase Akt (13). Akt is phosphorylated at
two sites, S308 by phosphatidylinositol-dependent kinase 1
(PDK1) and S473 by mTOR (40). Treatment of THP-1 cells
with Stx1 resulted in transient Akt phosphorylation at S473
(Fig. 5A), suggesting that mTOR activation by Stx1 is likely.
Akt activation peaked at a 6.8-fold increase 6 h after toxin
FIG. 4. Stx1 triggers increased cytosolic Ca2 levels in THP-1 cells. THP-1 cells were maintained in Ca2-containing medium and then treated
with the fluorescent Ca2 indicator Fluo-5F. Basal cytosolic Ca2 levels were determined for 10 min using the Zeiss Stallion live cell imaging
system. The first arrows indicate the addition of Stx1 (A) or (C) Stx1A	 to the cells. After measurement of Ca2 levels for 1 h, thapsigargin was
added to the cells (second arrows). Fluorescence intensities at 0-h time points and 1 h after Stx1 (B) or Stx1A	 (D) treatments were plotted for
three independent experiments. Asterisks (*) indicate statistically significant differences (P 0.05) in cytosolic Ca
2 levels. To examine the uptake
of extracellular Ca2, THP-1 cells were maintained in Ca2-chelated medium prior to the addition of Fluo-5F and Stx1 (E) or Stx1A	 (G).
Changes in intracellular Ca2 were measured as outlined above. (F and H) Statistical analysis of differences in cytosolic Ca2 levels at 0, 0.18, and
1 h after Stx1 or Stx1A	 treatment. a, statistically significant difference (P  0.05); b, not significant.
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administration and returned to basal levels 12 h after toxin
treatment. Stx1A	 also activated Akt, with similar kinetics. All
immunoblots were stripped and probed with antibody recog-
nizing total Akt protein as a control for equal protein loading.
To ensure that treatment of THP-1 cells with Stx1 resulted in
the activation of functional Akt, we immunoprecipitated Akt
from cell lysates, and the resultant immune complexes were
used in a kinase assay measuring phosphorylation of a syn-
thetic GSK-3 fusion protein as a substrate (P-GSK-3 fusion
protein; Fig. 5B). Stx1 treatment of THP-1 cells resulted in a
3.2-fold increase in Akt kinase function at 4 h with kinetics
closely corresponding to that of Akt phosphorylation shown in
Fig. 5A.
PI3K and Akt inhibitors block 4E-BP phosphorylation. To
link Stx1-induced PI3K and Akt activation with 4E-BP phos-
phorylation, THP-1 cells were treated with various concentra-
tions of wortmannin, LY294002, or Akt inhibitor VIII for 1 h
prior to stimulation with Stx1. Cell lysates were prepared and
4E-BP phosphorylation status determined by Western blotting
using phospho-T37/46-, -S65-, or -T70-specific anti-4E-BP an-
tibodies. Equal protein loading was determined using anti-
4E-BP antibodies. Wortmannin at a 100 nM concentration
(Fig. 6A) or LY294002 at 10 to 20 M (data not shown)
inhibited 4E-BP phosphorylation in Stx1-treated cells. Akt in-
hibitor VIII at 20 M was also effective in blocking 4E-BP
phosphorylation in Stx1-treated cells. Thus, signaling through
PI3K and Akt appears necessary to maintain 4E-BP basal
priming phosphorylation and for activation at T70 and S65
since the priming sites are necessary for subsequent phosphor-
ylation events (16).
mTOR inhibitor blocks Stx1-induced 4E-BP hyperphosphor-
ylation at T70 and S65. mTOR is a large (289-kDa) serine/
FIG. 5. Stx1 and Stx1A	 activate Akt in THP-1 cells. (A) THP-1 cells were stimulated with Stx1 or Stx1A	 for 1 to 16 h. At each time point,
cell lysates were prepared and Western blotting (WB) performed using antibodies specific for phospho-Akt (S473). Blots were stripped and
reprobed with antibodies recognizing total Akt for equal protein loading (bottom panel). C, lysates prepared from control cells maintained for 16 h
without Stx1. Band intensities were measured by densitometry, and n-fold changes are expressed beneath each lane. (B) THP-1 cells were treated
with Stx1 for 1 to 8 h. At each time point, cell lysates were prepared. Supernatants collected from the lysates were precleared and incubated with
an anti-Akt monoclonal antibody. An Akt kinase assay was performed with the resultant immunoprecipitates using a synthetic GSK-3 fusion
protein substrate in the presence of ATP. Proteins were then separated by SDS-PAGE and Western blotting performed using an antibody
recognizing phospho-GSK-3. A representative Western blot is shown in the upper panel. TCL, total cellular lysate; C, lysates from control
(unstimulated) cells; IgG, negative control. The bar graph shown in the lower panel is the n-fold-induction of Akt kinase activity following Stx1
treatment of THP-1 cells derived from at least three independent experiments. Asterisks (), significant difference (P  0.05) for toxin treatment
results versus those with control cells.
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threonine kinase which regulates both transcription and trans-
lation. mTOR is activated by growth factors and insulin in a
PI3K-dependent manner. Akt directly phosphorylates mTOR
at position S2448. The two major substrates of mTOR activity
are p70S6K, a kinase involved in ribosome biogenesis, and
4E-BP (1). To demonstrate that mTOR is involved in Stx1-
induced 4E-BP activation, THP-1 cells were treated with the
mTOR inhibitor rapamycin for 1 h prior to stimulation with
Stx1. Cell lysates were prepared and 4E-BP phosphorylation
status determined by Western blotting (Fig. 6B). As expected,
comparison of unstimulated control cells versus Stx1-stimu-
lated cells showed that phosphorylation at the T37/T46 prim-
ing sites was not altered by toxin treatment. Rapamycin treat-
ment failed to alter phosphorylation at these residues in
Stx1-treated cells (upper panel). In contrast, toxin treatment
triggered 4E-BP phosphorylation at T70 (center panel) and
S65 (lower panel), and rapamycin inhibited phosphorylation at
these positions in a dose-dependent manner. Thus, mTOR is
involved in signaling selectively regulating 4E-BP phosphory-
lation at T70 and S65.
MAPK cascades do not regulate 4E-BP phosphorylation.
Treatment of THP-1 cells with Stx1 leads to the prolonged
activation of MAPKs p38 and JNK, transient activation of
ERK1/2, enhanced eIF4E phosphorylation, and the expression
of cytokines (5). However, the activation of 4E-BP is reported
to be mediated through the PI3K/Akt/mTOR pathway inde-
pendently of MAPK cascades (52). To examine the roles of
MAPKs in Stx1-induced signaling for 4E-BP activation, we
treated cells with inhibitors of ERK, JNK, and p38 MAPK
cascades or treated cells with all three inhibitors for 1 h prior
to treatment with Stx1. Cell lysates were prepared and 4E-BP
phosphorylation status ascertained by Western blotting using
phospho-T37/46- and -S65-specific antibodies. None of the
MAPK inhibitors altered Stx1-mediated 4E-BP phosphoryla-
tion (data not shown). Although Stx1 activates MAPK signal-
ing cascades, these pathways do not appear to be involved in
signaling for 4E-BP phosphorylation.
Stx1 activation of Akt results in phosphorylation of GSK-
3/. Akt activation leads to the activation or inactivation of a
large number of substrates (43). Akt directly phosphorylates
and inactivates GSK-3/ on S9 or S21, respectively (10). To
detect GSK-3/ inactivation, THP-1 cells were treated with
Stx1 for various time periods. Western blotting was then per-
formed on lysates using anti-phospho-GSK-3/ antibodies.
Within 4 h of stimulation with Stx1, GSK-3/ showed in-
creased phosphorylation that was maintained up to 16 h after
treatment (Fig. 7A). To examine the role of PI3K and Akt in
toxin-mediated signaling leading to GSK-3/ inactivation, we
stimulated THP-1 cells with Stx1 in the presence of specific
PI3K and Akt inhibitors. Changes in phospho-GSK-3/ levels
were measured by Western blotting (Fig. 7B). The PI3K in-
hibitor wortmannin inhibited GSK-3/ phosphorylation at
the lowest (50 nM) inhibitor concentration tested. The Akt
inhibitor also blocked GSK-3/ phosphorylation, with opti-
mal inhibition noted at 20 M. The inhibitors alone did not
alter GSK-3/ phosphorylation (data not shown). These data
suggest that signaling through PI3K/Akt is essential for GSK-
3/ inactivation.
Role of PI3K/Akt/mTOR pathway in cytokine production.
To study the role of the PI3K/Akt/mTOR pathway in cytokine
expression, we observed the effects of PI3K, Akt, mTOR, and
GSK-3/ inhibitors on Stx1-induced soluble cytokine produc-
tion by THP-1 cells (Fig. 8A and B). Cells were treated with
wortmannin, Akt inhibitor VIII, rapamycin, or GSK-3/ in-
hibitor IX for 1 h. To some cells, Stx1 was added and incuba-
tion continued for 24 h. Cell supernatants were collected for
quantification of TNF- and IL-1. As previously reported,
Stx1 treatment induced increased cytokine expression by
THP-1 cells in vitro (34). PI3K/Akt/mTOR inhibitor treat-
ments alone resulted in dose-dependent increases in TNF-
and IL-1 production compared to results for control (un-
treated) cells. However, cells pretreated with the inhibitors and
Stx1 showed significant dose-dependent increases in cytokine
FIG. 6. PI3K, Akt, and mTOR inhibitors block 4E-BP phosphory-
lation. THP-1 cells were incubated with the indicated concentrations of
PI3K inhibitor (wortmannin; W) or Akt Inhibitor VIII (Akt In) (A) or
mTOR inhibitor rapamycin (R) (B) for 1 h prior to the addition of Stx1
(400 ng/ml) for 1 h. Lysates were prepared and Western blotting (WB)
performed using antibodies recognizing phosphorylated 4E-BP resi-
dues T37 and T46, T70, and S65. Blots were stripped and reprobed
with antibody recognizing total 4E-BP for equal protein loading. Con-
trol, unstimulated cells. The results shown are representative of at least
three independent experiments.
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expression. In contrast, in cells treated with GSK-3/ inhibi-
tor IX and Stx1, we observed a 50% reduction in soluble
TNF- production and a 20% reduction in soluble IL-1 pro-
duction compared to results for cells treated with Stx1 alone.
Thus, 24 h after toxin treatment, the PI3K/Akt/mTOR pathway
appears to negatively regulate soluble proinflammatory cyto-
kine production by Stx1-treated THP-1 cells. The precise
mechanism of negative regulation is unknown, but our data
suggest that Stx1-induced PI3K/Akt/mTOR activation may de-
crease cytokine expression in part by blocking the action of a
positive cytokine regulator, GSK-3/.
To confirm the data on the negative role of Akt in Stx1-
induced cytokine expression using pharmacological inhibitors,
we used siRNAs to knock down Akt expression. THP-1 cells
were transfected with Akt-specific siRNA or nonspecific con-
trol siRNA for 48 h and were then stimulated with Stx1. The
cells were lysed and Western blotting performed. We detected
a 54% decrease in total Akt protein in cells transfected with
Akt-specific siRNA normalized against actin levels (Fig. 9A).
Cell supernatants prepared from all transfected cells were an-
alyzed by ELISA for TNF- and IL-1 expression (Fig. 9B and
C). TNF- and IL-1 production was increased 69% and 49%,
respectively, in Akt siRNA-transfected cells. These data sup-
port a negative role for signaling through the Akt pathway in
cytokine production.
DISCUSSION
Human adherent macrophage-like THP-1 cells respond to
Stxs by induction and expression of proinflammatory cytokines
(34). The localized expression of TNF- and IL-1 may con-
tribute to the pathogenesis of hemorrhagic colitis and acute
renal failure, since these cytokines regulate expression of Gb3
biosynthetic genes leading to increased toxin receptor expres-
sion on endothelial cells (44). Prolonged expression of proin-
flammatory cytokines leads to pathological consequences.
Therefore, cytokine expression is tightly regulated at transcrip-
tional, translational, and posttranslational stages. Our studies
suggest that Stxs regulate cytokine expression at multiple lev-
els. Toxin-induced cytokine expression occurs, in part, through
activation of the stress-associated protein kinases leading to
activation of the transcriptional factors NF-B and AP-1 (5, 38,
53). Translational control mechanisms may include changes in
mRNA stability and translation initiation, alternative RNA
splicing events, and RNA nucleocytoplasmic transport (14).
Cytokine and chemokine mRNA transcripts induced by Stxs
appear to be more stable than transcripts induced by LPS or
TNF- (19, 20, 49). The precise mechanisms by which Stxs
stabilize mRNA transcripts remain to be characterized. How-
ever, a deadenylation-dependent 5 3 3 mRNA decay path-
way is initiated following decapping of the 5-m7GpppN cap
(7). Thus, translation rates of individual mRNAs may reflect
the relative ability to assemble translational initiation com-
plexes versus assembly of translational repression or degrada-
tion complexes at the 5 cap structure (8). In this regard, we
have shown that treatment of THP-1 cells with Stx1 increases
eIF4E phosphorylation through an ERK1/2- and p38 MAPK/
Mnk1-dependent signaling cascade. MAPK and Mnk1 inhibi-
tors reduce cytokine expression by THP-1 cells upon exposure
to Stx1 (5). Collectively, these data suggest that Stxs may rap-
idly regulate cytokine production, in part, by increased effi-
ciency of translation initiation and reduced transcript degra-
dation by blocking of transcript decapping and decay.
The rate-limiting step in formation of the eIF4F complex is
binding of eIF4E to the 5 cap. eIF4E activity is inhibited by a
family of repressors called 4E-BP. In the partially phosphory-
FIG. 7. PI3K/Akt activation by Stx1 results in the activation of the downstream substrate GSK-3/. (A) THP-1 cells were stimulated with Stx1,
and at each time point, cell lysates were prepared and Western blotting (WB) performed using antibodies specific for phospho-GSK-3/. Blots
were stripped and reprobed with antibodies recognizing actin for equal protein loading (bottom panel). C, lysates prepared from control cells
maintained for 16 h without Stx1. (B) THP-1 cells were treated with the indicated amounts of PI3K (wortmannin) or Akt inhibitors for 1 h prior
to stimulation with Stx1 for 1 h (PI3K inhibition) or 4 h (Akt inhibition). Cell lysates were prepared and Western blotting performed using
antibodies specific for phospho-GSK-3/. Blots were stripped and reprobed with antibodies recognizing actin for equal protein loading (bottom
panel). Results shown are representative of at least three independent experiments.
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lated state, 4E-BP interacts strongly with eIF4E, while hyper-
phosphorylation of 4E-BP leads to detachment from eIF4E,
which may subsequently bind to the 5 cap of mRNAs (30).
Following binding to the scaffolding protein eIF4G, eIF4E is
phosphorylated at S209 by the kinases Mnk1 and Mnk2. We
show here that in macrophage-like THP-1 cells, 4E-BP is con-
stitutively phosphorylated at T37/T46, and treatment with pu-
rified Stx1 failed to alter phosphorylation at these residues.
Following toxin treatment, we noted the rapid (within 1 h) but
transient phosphorylation of 4E-BP at S65. Our data are in
accordance with the findings of Colpoys et al. (9) showing that
treatment of the intestinal epithelial cell line Hct-8 with Stx1
resulted in increased 4E-BP phosphorylation at S65. Toxin-
mediated increases in phosphorylation at S65 may reduce the
affinity of 4E-BP for eIF4E, since we have shown a lack of
hyperphosphorylated 4E-BP associated with phospho-eIF4E/
m7GTP-Sepharose 4B complexes. MAPK and Mnk1 activa-
tion, eIF4E phosphorylation, and cytokine expression by Stx1-
treated THP-1 cells require toxin enzymatic activity; treatment
of cells with purified Stx1A	 or Stx1 B subunits did not trigger
these responses (5, 20). In contrast, Stx1A	 triggered 4E-BP
hyperphosphorylation, although to a lesser extent than Stx1,
suggesting that signaling pathways involved in this response
may not require delivery of functional Stxs to the ER. Whether
the highly transient nature of 4E-BP activation by Stx1 limits
cytokine expression will require additional experiments.
We have shown that Stx1-mediated 4E-BP hyperphosphory-
lation occurs through the PI3K/Akt/mTOR pathway. PI3K is a
membrane-associated lipid-modifying enzyme containing a
regulatory subunit (p85) and a catalytic subunit (p110). Fol-
lowing phosphorylation of p85 tyrosine residues, activated
PI3K phosphorylates the D3 position of the inositol ring in
plasma membrane lipids to generate phospholipid second mes-
sengers, further leading to release of Ca2 ions from the ER.
Changes in membrane phospholipids localize kinases contain-
ing pleckstrin homology domains to the membrane, including
PDK1 and Akt (4, 43). PDK1 and mTOR activate Akt by
phosphorylation at positions T308 and S473, respectively (21,
40). We have shown that Stx1 activated PI3K, which may lead
to generation of phospholipid second messengers, release of
Ca2 from intracellular stores, and activation of Akt in mac-
rophage-like THP-1 cells. In accordance with the data showing
that optimal 4E-BP hyperphosphorylation requires toxin enzy-
matic activity, Stx1A	 and B subunits only partially activated
FIG. 8. Effect of pretreatment with PI3K (wortmannin), Akt (Akt inhibitor VIII), mTOR (rapamycin), or GSK-3/ (GSK-3/ inhibitor IX)
inhibitor on Stx1-induced soluble TNF- and IL-1 production. Differentiated THP-1 cells were treated with the inhibitors for 1 h, and Stx1 was
added for 24 h. Cell supernatants were collected. Soluble TNF- and IL-1 were quantified using ELISA kits. All values are expressed in pg/ml 

SEM. Asterisks (*) represent significant differences (P 0.05) between results with Stx1 treatment versus those with Stx1-plus-inhibitor treatment.
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PI3K. Signaling through the PI3K pathway alone, however, is
not sufficient for cytokine production; neither Stx1A	 nor B
subunits will elicit TNF- or IL-1 expression from THP-1
cells. Cytokine expression appears to require the retrograde
transport of functional toxin to the ER, activation of signaling
pathways, and the phosphorylation of eIF4E (5, 27).
Consistent with PI3K activation, we noted increased cytoso-
lic Ca2 levels in Stx1- and Stx1A	-treated cells. Recently we
showed that Stx1 activates the ER stress response in undiffer-
entiated THP-1 cells via a mechanism requiring the retrograde
translocation of functional toxin to the ER (27). Stx1 activation
of ER stress also triggered the release of Ca2 from ER stores.
Collectively, these data suggest that Stxs may alter normal
Ca2 homeostasis via multiple mechanisms. Alterations in in-
tracellular Ca2 stores may lead to the activation of a broad
array of signaling cascades (6). The role of Stx1-mediated
changes in Ca2 localization and regulation of cytokine expres-
sion will require further studies.
The precise role of the PI3K/Akt/mTOR pathway in regu-
lation of cytokine expression has not been fully characterized.
Thomas et al. (48) reported that respiratory syncytial virus
infection of airway epithelial cells resulted in PI3K, Akt, and
GSK-3 activation, leading to NF-B-mediated induction of
cytokine gene expression. Inhibition of PI3K activation re-
sulted in rapid apoptotic cell death and blocked respiratory
syncytial virus-induced NF-B activation. Reddy et al. (36)
showed that TNF- induced PI3K and Akt activation in the
human myeloid cell line U937, and PI3K activation was essen-
tial for increased expression of an NF-B-dependent reporter
gene. Based on these earlier studies and our demonstration of
a positive role for Stx1-induced eIF4E activation in cytokine
expression, we predicted that 4E-BP hyperphosphorylation
would be associated with increased eIF4E release and in-
creased cytokine production. We found, however, that 4E-BP
activation is short-lived, correlating with the transient increase
in total protein synthesis we previously noted in toxin-treated
THP-1 cells (12). Transfection of THP-1 cells with Akt-specific
siRNA and inhibitors of PI3K, Akt, and mTOR all increased
cytokine production 24 h after Stx1 treatment. Moreover, the
kinase inhibitors alone modestly increased TNF- and IL-1
production. Thus, our findings are in accordance with those of
earlier studies showing that inhibition of the PI3K/Akt path-
way increased cytokine and tissue factor expression induced by
LPS treatment of murine and human macrophages (18, 26, 29),
and activation of the PI3K/Akt pathway by insulin reduced
inflammation in mice administered LPS (24). A number of
mechanisms may be contributing to PI3K/Akt-mediated nega-
tive regulation of cytokine expression. For example, it is known
that LPS triggering of the PI3K/Akt pathway reduced MAPK
and NF-B activities through the activation of the negative
regulators Raf-1 and IB kinase and inactivation of the posi-
tive regulator GSK-3/, leading to reduced activation of tran-
scription factors involved in cytokine gene expression (18).
Recently Martin et al. (31) showed that GSK-3/ is a key
regulator in determining the relative expression of pro- and
anti-inflammatory mediators by human peripheral blood
monocytes. Following GSK-3/ inhibition, Toll-like receptor
2 (TLR2), TLR4, TLR5, and TLR9 agonists induced IL-10
FIG. 9. Effect of Akt knockdown on Stx1-induced production of soluble cytokines. Differentiated THP-1 cells were transfected with Akt-specific
siRNA or a nonspecific siRNA control for 48 h. Cells were stimulated with Stx1 for 24 h. (A) Cell lysates were prepared and Western blotting (WB)
performed using total Akt antibody. Blots were stripped and reprobed with antibody recognizing actin for equal protein loading. Control (UT),
untransfected cells; Control siRNA, nonspecific siRNA. (B and C) Cell supernatants were collected, and soluble TNF- and IL-1 were quantified
by ELISA. All values are expressed in pg/ml 
 SEM. Asterisks (*) represent significant differences (P  0.05) between results with Stx1 alone
versus those with Stx1 plus Akt siRNA transfection. RC, reagent control; Con. Si RNA, nonspecific siRNA.
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production while suppressing production of the proinflamma-
tory cytokines IL-1, IL-6, IL-12p40, and gamma interferon.
Akt-dependent phosphorylation of GSK-3/ is associated
with the abrogation of positive signaling for cytokine expres-
sion, and we have shown that Akt activated by Stx1 is func-
tional in that GSK-3/ is phosphorylated. Thus, Stx-mediated
PI3K/Akt/mTOR activation may have a brief positive effect
leading to 4E-BP hyperphosphorylation but may ultimately
have a negative influence on cytokine expression due to in-
creased phosphorylation and inactivation of GSK-3/.
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